Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
Clinical trial NCT02230176 · COMPLETED
Trial details
- NCT number
- NCT02230176
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-01
- Primary completion
- 2024-04-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.